Bonapace et al. demonstrated, that anti-CCL2 treatment decreased breast cancer metastases in mice, but interruption of anti-CCL2 treatment precipitated an unexpected influx of monocytes into the metastatic site and overshooting IL-6 levels within the metastatic microenvironment. This evidence concerns the gene CCL2 and breast carcinoma.